AstraZeneca PLC (LON:AZN) Receives £101.62 Average PT from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is £101.62 ($136.08).

A number of brokerages have issued reports on AZN. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £110 ($147.30) price target on shares of AstraZeneca in a research note on Tuesday, September 3rd. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, July 25th. Jefferies Financial Group boosted their price target on shares of AstraZeneca from GBX 71 ($0.95) to GBX 74 ($0.99) and gave the stock a “hold” rating in a research note on Tuesday, July 2nd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, September 16th. Finally, Berenberg Bank reissued a “buy” rating and set a £150 ($200.86) target price on shares of AstraZeneca in a research note on Monday, September 2nd.

AstraZeneca Price Performance

Shares of AZN stock opened at £116.86 ($156.48) on Friday. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market capitalization of £181.13 billion, a PE ratio of 3,745.51, a price-to-earnings-growth ratio of 0.88 and a beta of 0.17. The firm’s 50-day moving average is £125.12 and its two-hundred day moving average is £120.02. AstraZeneca has a 12 month low of GBX 9,461 ($126.69) and a 12 month high of £133.88 ($179.27).

AstraZeneca Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were given a dividend of GBX 77.60 ($1.04) per share. The ex-dividend date was Thursday, August 8th. This represents a dividend yield of 0.64%. AstraZeneca’s dividend payout ratio is presently 7,500.00%.

Insiders Place Their Bets

In related news, insider Michel Demare bought 2,000 shares of the stock in a transaction on Friday, September 13th. The shares were purchased at an average price of GBX 118 ($1.58) per share, with a total value of £2,360 ($3,160.15). 0.04% of the stock is currently owned by insiders.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.